Skip to main content

Table 3 Characteristics of participants who completed the SF-12v2 between 2012 and 2016

From: Measurement properties of the 12-item Short Form Health Survey version 2 in Australians with lung cancer: a Rasch analysis

 

All participants

(n = 342)

Sociodemographic characteristics

Male, n (%)

191

(56)

Age, mean (SD)

67.3

(10.9)

Age group, n (%)

 < 70 years

190

(56)

 ≥ 70 years

152

(44)

Country of birth, n (%)

 Australia

241

(71)

 Not Australia

91

(27)

Smoking status, n (%)

 Never smoked

28

(8)

 Ex-smoker

211

(62)

 Current smoker

83

(24)

Past medical history, n (%)

 Diabetes

53

(16)

 Renal insufficiency (needing dialysis)

5

(2)

 Myocardial infarction

66

(19)

 Respiratory co-morbidity (FEV1 < 66%)

47

(14)

 Neoplasm co-morbidity

76

(22)

Hospital type, n (%)

 Public

215

(63)

 Private

127

(37)

Clinical characteristics

Lung cancer type, n (%)

 Non-small cell lung cancer

288

(84)

 Small cell lung cancer

35

(10)

 Neuroendocrine

7

(2)

 Other lung cancer

9

(3)

TNM staging, n (%)

 Non-small cell lung cancer

  Localised (I-II)

76

(26)

  Locally advanced (III)

87

(30)

  Metastatic (IV)

40

(14)

  Unable to assess

85

(30)

 Small cell lung cancer

  Extensive

20

(57)

  Limited

12

(34)

  Not stated

3

(9)

Active lung cancer treatment, n (%)

 Surgical resections

173

(51)

 Chemotherapy

168

(49)

 Radiotherapy

99

(29)

ECOG performance status, n (%)

 Independent (0–1)

206

(60)

 Assistance (2–4)

136

(40)

  1. SD, standard deviation FEV1, forced expiratory volume in one second; TNM staging, tumour, node and metastasis staging; ECOG, Eastern Cooperative Oncology Group